• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高危神经母细胞瘤的治疗

Treatment of High-Risk Neuroblastoma.

作者信息

Krystal Julie, Foster Jennifer H

机构信息

Zucker Hofstra School of Medicine, Department of Pediatrics, Cohen Children's Medical Center, New Hyde Park, NY 11040, USA.

Department of Pediatrics, Baylor College of Medicine, Texas Children's Cancer Center, Houston, TX 77030, USA.

出版信息

Children (Basel). 2023 Jul 28;10(8):1302. doi: 10.3390/children10081302.

DOI:10.3390/children10081302
PMID:37628301
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10453838/
Abstract

High-risk neuroblastoma is a highly aggressive solid tumor that most commonly presents in early childhood. Advances in treatment through decades of clinical trials and research have led to improved outcomes. This review provides an overview of the current state of treatment for high-risk neuroblastoma.

摘要

高危神经母细胞瘤是一种侵袭性很强的实体瘤,最常见于幼儿期。经过数十年的临床试验和研究,治疗方法取得了进展,带来了更好的治疗效果。本综述概述了高危神经母细胞瘤的当前治疗状况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5a2/10453838/e478e7c41d8e/children-10-01302-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5a2/10453838/e478e7c41d8e/children-10-01302-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5a2/10453838/e478e7c41d8e/children-10-01302-g001.jpg

相似文献

1
Treatment of High-Risk Neuroblastoma.高危神经母细胞瘤的治疗
Children (Basel). 2023 Jul 28;10(8):1302. doi: 10.3390/children10081302.
2
Nervous system: Embryonal tumors: Neuroblastoma.神经系统:胚胎性肿瘤:神经母细胞瘤。
Atlas Genet Cytogenet Oncol Haematol. 2020 Jul;24(7):284-290. doi: 10.4267/2042/70771.
3
Difluoromethylornithine (DFMO) and Neuroblastoma: A Review.二氟甲基鸟氨酸(DFMO)与神经母细胞瘤:综述
Cureus. 2023 Apr 17;15(4):e37680. doi: 10.7759/cureus.37680. eCollection 2023 Apr.
4
State of the art in oncology: high risk neuroblastoma, alveolar rhabdomyosarcoma, desmoplastic small round cell tumor, and POST-TEXT 3 and 4 hepatoblastoma.肿瘤学的最新进展:高危神经母细胞瘤、肺泡横纹肌肉瘤、促结缔组织增生性小圆细胞肿瘤以及POST-TEXT 3和4期肝母细胞瘤。
J Pediatr Surg. 2014 Feb;49(2):233-40. doi: 10.1016/j.jpedsurg.2013.11.029. Epub 2013 Nov 15.
5
Genetic Predisposition to Neuroblastoma.神经母细胞瘤的遗传易感性
Children (Basel). 2018 Aug 31;5(9):119. doi: 10.3390/children5090119.
6
Advances in emerging drugs for the treatment of neuroblastoma.治疗神经母细胞瘤的新型药物进展
Expert Opin Emerg Drugs. 2017 Mar;22(1):63-75. doi: 10.1080/14728214.2017.1294159. Epub 2017 Feb 22.
7
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.大剂量化疗及自体造血干细胞救援用于高危神经母细胞瘤患儿
Cochrane Database Syst Rev. 2015 Oct 5;2015(10):CD006301. doi: 10.1002/14651858.CD006301.pub4.
8
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.大剂量化疗及自体造血干细胞救援用于高危神经母细胞瘤患儿
Cochrane Database Syst Rev. 2013 Aug 22(8):CD006301. doi: 10.1002/14651858.CD006301.pub3.
9
New therapeutic targets for the treatment of high-risk neuroblastoma.治疗高危神经母细胞瘤的新治疗靶点
J Cell Biochem. 2009 May 1;107(1):46-57. doi: 10.1002/jcb.22094.
10
Nanomedicines and cell-based therapies for embryonal tumors of the nervous system.神经母细胞瘤的纳米药物和基于细胞的疗法。
J Control Release. 2022 Aug;348:553-571. doi: 10.1016/j.jconrel.2022.06.010. Epub 2022 Jun 17.

引用本文的文献

1
Therapeutic Innovation in Pediatric Neuroblastoma: Age and Stage-Specific Strategies from Prenatal to Early Childhood-A Review Article.小儿神经母细胞瘤的治疗创新:从产前到幼儿期的年龄和阶段特异性策略——一篇综述文章
Iran J Child Neurol. 2025 Jun 25;19(3):9-29. doi: 10.22037/ijcn.v19i3.48040. eCollection 2025 Summer.
2
Predictive model based on blood cell analysis and coagulation function indicators for neuroblastic tumors staging diagnosis.基于血细胞分析和凝血功能指标的神经母细胞瘤分期诊断预测模型
Front Oncol. 2025 Jul 25;15:1575863. doi: 10.3389/fonc.2025.1575863. eCollection 2025.
3
The Role of V-ATPase ATP6V0D1 Subunit in Chemoresistance and Ellipticine-Induced Cytoplasmic Vacuolation in Neuroblastoma Cells.

本文引用的文献

1
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.GD2-CART01 治疗复发/难治高危神经母细胞瘤。
N Engl J Med. 2023 Apr 6;388(14):1284-1295. doi: 10.1056/NEJMoa2210859.
2
Genomic ALK alterations in primary and relapsed neuroblastoma.原发和复发神经母细胞瘤中的基因组 ALK 改变。
Br J Cancer. 2023 Apr;128(8):1559-1571. doi: 10.1038/s41416-023-02208-y. Epub 2023 Feb 17.
3
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor.
V-ATP酶ATP6V0D1亚基在神经母细胞瘤细胞化疗耐药及椭圆玫瑰树碱诱导的细胞质空泡化中的作用
Mol Cell Oncol. 2025 Jun 17;12(1):2518774. doi: 10.1080/23723556.2025.2518774. eCollection 2025.
4
Interplay Between the Epigenome, the Microenvironment, and the Immune System in Neuroblastoma.神经母细胞瘤中表观基因组、微环境与免疫系统之间的相互作用
Cancers (Basel). 2025 May 29;17(11):1812. doi: 10.3390/cancers17111812.
5
Selective targeting of genome amplifications and repeat elements by CRISPR-Cas9 nickases to promote cancer cell death.利用CRISPR-Cas9切口酶对基因组扩增和重复元件进行选择性靶向以促进癌细胞死亡。
Nat Commun. 2025 Jun 2;16(1):5126. doi: 10.1038/s41467-025-60160-2.
6
Colchicine Binding Site Tubulin Inhibitors Impair Vincristine-Resistant Neuroblastoma Cell Function.秋水仙碱结合位点微管蛋白抑制剂损害长春新碱耐药神经母细胞瘤细胞功能。
Molecules. 2025 May 16;30(10):2186. doi: 10.3390/molecules30102186.
7
From Local to International Approach: Prognostic Factors and Treatment Outcomes in Neuroblastoma-A 30-Year Single-Center Retrospective Analysis.从局部到国际的方法:神经母细胞瘤的预后因素和治疗结果——一项30年单中心回顾性分析
Children (Basel). 2025 Apr 19;12(4):525. doi: 10.3390/children12040525.
8
LGALS3BP antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth.半乳糖凝集素3结合蛋白抗体药物偶联物增强肿瘤浸润淋巴细胞,并与免疫疗法协同作用以抑制神经母细胞瘤生长。
J Transl Med. 2025 Apr 11;23(1):431. doi: 10.1186/s12967-025-06434-1.
9
Emerging clinical and research approaches in targeted therapies for high-risk neuroblastoma.高危神经母细胞瘤靶向治疗中的新兴临床与研究方法。
Front Oncol. 2025 Mar 4;15:1553511. doi: 10.3389/fonc.2025.1553511. eCollection 2025.
10
Iwilfin (eflornithine) approved by the FDA as the first and only oral maintenance therapy for high-risk neuroblastoma in adult and pediatric patients: Narrative review.依维莫司(eflornithine)获 FDA 批准,成为首个也是唯一一个用于成人和儿科高危神经母细胞瘤患者的口服维持治疗药物:叙述性综述。
Medicine (Baltimore). 2024 Nov 29;103(48):e40662. doi: 10.1097/MD.0000000000040662.
接受伊立替康/替莫唑胺/地努图希单抗/粒细胞-巨噬细胞集落刺激因子治疗的复发高危神经母细胞瘤患者的无进展生存期和反应模式
J Clin Oncol. 2023 Jan 20;41(3):508-516. doi: 10.1200/JCO.22.01273. Epub 2022 Oct 7.
4
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease.诱导后治疗对有诱导后残留病的高危神经母细胞瘤患者的疗效。
Cancer. 2022 Aug 1;128(15):2967-2977. doi: 10.1002/cncr.34263. Epub 2022 Jun 6.
5
High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes.高危神经母细胞瘤和复发性神经母细胞瘤:追求更高的治愈率和更好的预后。
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-13. doi: 10.1200/EDBK_349783.
6
Current pediatric cancer survivorship practices: a report from the Children's Oncology Group.当前儿科癌症生存者照护实践:来自儿童肿瘤学组的报告。
J Cancer Surviv. 2023 Aug;17(4):1139-1148. doi: 10.1007/s11764-021-01157-w. Epub 2022 Jan 31.
7
Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A.化疗免疫治疗改善高危神经母细胞瘤患儿预后:hu14.18K322A 二线治疗高危神经母细胞瘤的 II 期研究更新结果
J Clin Oncol. 2022 Feb 1;40(4):335-344. doi: 10.1200/JCO.21.01375. Epub 2021 Dec 6.
8
Roles of Surgery in the Treatment of Patients With High-Risk Neuroblastoma in the Children Oncology Group Study: A Systematic Review and Meta-Analysis.儿童肿瘤学组研究中手术在高危神经母细胞瘤患者治疗中的作用:一项系统评价和荟萃分析
Front Pediatr. 2021 Oct 13;9:706800. doi: 10.3389/fped.2021.706800. eCollection 2021.
9
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group.修正的神经母细胞瘤风险分类系统:来自儿童肿瘤协作组的报告。
J Clin Oncol. 2021 Oct 10;39(29):3229-3241. doi: 10.1200/JCO.21.00278. Epub 2021 Jul 28.
10
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.随机 II 期试验:间碘苄胍(MIBG)对比 MIBG、长春新碱和伊立替康,用于治疗复发或难治性神经母细胞瘤:来自 NANT 联盟的报告。
J Clin Oncol. 2021 Nov 1;39(31):3506-3514. doi: 10.1200/JCO.21.00703. Epub 2021 Jul 16.